FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385173213> ?p ?o ?g. }

• W4385173213 endingPage "1333" @default.
• W4385173213 startingPage "1319" @default.
• W4385173213 abstract "Ixekizumab (IXE) is an IgG4-type monoclonal antibody targeting IL-17A indicated alone or in combination with methotrexate, for the treatment of active psoriatic arthritis (PsA) in adult patients with insufficient response or with intolerance to one or more disease-modifying anti-rheumatic drug (DMARD) therapy. The PRO-STIP study aimed to describe persistence, patient characteristics, treatment patterns, and effectiveness in patients with PsA receiving IXE in a real-world clinical setting in Spain.This was an observational, multicentric, retrospective, longitudinal study in adult PsA patients who started IXE between January 2019 and December 2020, with at least 24 weeks of follow-up. A descriptive analysis of patient characteristics and treatment patterns was performed. The primary objective, treatment persistence, was estimated by Kaplan-Meier survival curve. Effectiveness was evaluated by Disease Activity in Psoriatic Arthritis (DAPSA) scores at baseline and at 12 and 24 weeks.Eighty-nine patients met the selection criteria (55.1% women and mean age 51.5 years). The median time from PsA diagnosis to starting IXE was 7.7 years (IQR 3.4-14.6). Prior to IXE, 95.5% patients had been treated with at least one biologic or targeted synthetic DMARD (b/tsDMARD). The observed persistence rates were 95.5%, 84.3% and 68.5% at 24, 48, and 104 weeks, respectively. The median persistence was not reached in the study period (mean persistence, 86.9 [95% CI 80.6-93.2] weeks). Twenty-eight (31.5%) patients discontinued IXE, 19 patients (21.3%) due to loss of effectiveness and two patients (2.2%) due to adverse events. In patients receiving treatment and with available effectiveness assessment (n = 24), DAPSA decreased significantly from baseline 23.7 (95% CI 19.5-27.9) to 14.8 (95% CI 10.5-19.2) at 12 weeks (p = 0.005) and 14.3 (95% CI 11.1-17.4) at 24 weeks (p = 0.004).PsA patients treated with IXE in a real-world setting show high treatment persistence through 104 weeks and improvements in disease activity after treatment initiation. This suggests that IXE could be an effective treatment for patients with PsA.Date of registration: 25th May 2021." @default.
• W4385173213 created "2023-07-24" @default.
• W4385173213 creator A5019951649 @default.
• W4385173213 creator A5028203693 @default.
• W4385173213 creator A5030557007 @default.
• W4385173213 creator A5043427430 @default.
• W4385173213 creator A5047620190 @default.
• W4385173213 creator A5053930201 @default.
• W4385173213 creator A5054708705 @default.
• W4385173213 creator A5069395382 @default.
• W4385173213 creator A5070760495 @default.
• W4385173213 creator A5073102709 @default.
• W4385173213 creator A5075426908 @default.
• W4385173213 creator A5079843277 @default.
• W4385173213 creator A5088126751 @default.
• W4385173213 date "2023-07-23" @default.
• W4385173213 modified "2023-10-12" @default.
• W4385173213 title "Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study" @default.
• W4385173213 cites W2258730682 @default.
• W4385173213 cites W2765116545 @default.
• W4385173213 cites W2782272615 @default.
• W4385173213 cites W2806678383 @default.
• W4385173213 cites W2885351685 @default.
• W4385173213 cites W2890774149 @default.
• W4385173213 cites W3004681236 @default.
• W4385173213 cites W3010468919 @default.
• W4385173213 cites W3016116087 @default.
• W4385173213 cites W3027539208 @default.
• W4385173213 cites W3036984336 @default.
• W4385173213 cites W3098733875 @default.
• W4385173213 cites W3166431541 @default.
• W4385173213 cites W3201047607 @default.
• W4385173213 cites W3207892227 @default.
• W4385173213 cites W3214135074 @default.
• W4385173213 cites W4220809429 @default.
• W4385173213 cites W4281788390 @default.
• W4385173213 cites W4307970544 @default.
• W4385173213 cites W4313649029 @default.
• W4385173213 doi "https://doi.org/10.1007/s40744-023-00584-8" @default.
• W4385173213 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37481752" @default.
• W4385173213 hasPublicationYear "2023" @default.
• W4385173213 type Work @default.
• W4385173213 citedByCount "0" @default.
• W4385173213 crossrefType "journal-article" @default.
• W4385173213 hasAuthorship W4385173213A5019951649 @default.
• W4385173213 hasAuthorship W4385173213A5028203693 @default.
• W4385173213 hasAuthorship W4385173213A5030557007 @default.
• W4385173213 hasAuthorship W4385173213A5043427430 @default.
• W4385173213 hasAuthorship W4385173213A5047620190 @default.
• W4385173213 hasAuthorship W4385173213A5053930201 @default.
• W4385173213 hasAuthorship W4385173213A5054708705 @default.
• W4385173213 hasAuthorship W4385173213A5069395382 @default.
• W4385173213 hasAuthorship W4385173213A5070760495 @default.
• W4385173213 hasAuthorship W4385173213A5073102709 @default.
• W4385173213 hasAuthorship W4385173213A5075426908 @default.
• W4385173213 hasAuthorship W4385173213A5079843277 @default.
• W4385173213 hasAuthorship W4385173213A5088126751 @default.
• W4385173213 hasBestOaLocation W43851732131 @default.
• W4385173213 hasConcept C126322002 @default.
• W4385173213 hasConcept C127413603 @default.
• W4385173213 hasConcept C16005928 @default.
• W4385173213 hasConcept C187320778 @default.
• W4385173213 hasConcept C2776260265 @default.
• W4385173213 hasConcept C2777077863 @default.
• W4385173213 hasConcept C2779745271 @default.
• W4385173213 hasConcept C2779786854 @default.
• W4385173213 hasConcept C2780564577 @default.
• W4385173213 hasConcept C2781009140 @default.
• W4385173213 hasConcept C71924100 @default.
• W4385173213 hasConceptScore W4385173213C126322002 @default.
• W4385173213 hasConceptScore W4385173213C127413603 @default.
• W4385173213 hasConceptScore W4385173213C16005928 @default.
• W4385173213 hasConceptScore W4385173213C187320778 @default.
• W4385173213 hasConceptScore W4385173213C2776260265 @default.
• W4385173213 hasConceptScore W4385173213C2777077863 @default.
• W4385173213 hasConceptScore W4385173213C2779745271 @default.
• W4385173213 hasConceptScore W4385173213C2779786854 @default.
• W4385173213 hasConceptScore W4385173213C2780564577 @default.
• W4385173213 hasConceptScore W4385173213C2781009140 @default.
• W4385173213 hasConceptScore W4385173213C71924100 @default.
• W4385173213 hasIssue "5" @default.
• W4385173213 hasLocation W43851732131 @default.
• W4385173213 hasLocation W43851732132 @default.
• W4385173213 hasOpenAccess W4385173213 @default.
• W4385173213 hasPrimaryLocation W43851732131 @default.
• W4385173213 hasRelatedWork W2169844342 @default.
• W4385173213 hasRelatedWork W2195057011 @default.
• W4385173213 hasRelatedWork W2793374690 @default.
• W4385173213 hasRelatedWork W3106721720 @default.
• W4385173213 hasRelatedWork W3194985274 @default.
• W4385173213 hasRelatedWork W4220793238 @default.
• W4385173213 hasRelatedWork W4313502673 @default.
• W4385173213 hasRelatedWork W4382931191 @default.
• W4385173213 hasRelatedWork W4383186745 @default.
• W4385173213 hasRelatedWork W4386084427 @default.
• W4385173213 hasVolume "10" @default.
• W4385173213 isParatext "false" @default.
• W4385173213 isRetracted "false" @default.

• next